Brucella abortus is a Gram-negative bacterium that survives inside host cells as a facultative intracellular pathogen (1). It infects humans and cattle, causing a chronic inflammatory disease known as brucellosis. In humans, brucellosis symptoms include undulant fever, endocarditis, arthritis, and osteomyelitis (2). In cattle, B. abortus causes miscarriage and infertility, leading to serious economic losses (3). The host immune response to B. abortus is initiated through innate immune mechanisms that recognize bacterial components and provide the necessary signals for the induction of an adaptive immune response (4). This specific adaptive immune response, which is Th1 mediated, plays a critical role in host control of B. abortus (5). The Th1-driven immune response to B. abortus involves CD4 ϩ and CD8 ϩ T lymphocytes, macrophages, dendritic cells (DCs), and proinflammatory cytokines such as gamma interferon (IFN-␥) and interleukin-12 (IL-12) (6-9).There is a growing interest in the immunoregulatory role of lipid mediators in infectious diseases (10-12). 5-Lipoxygenase (5-LO) is an enzyme required for the biosynthesis of two important groups of lipid mediators, leukotrienes (LTs) and lipoxins (LXs), both derived from arachidonic acid. 5-LO is made in several cell types, including neutrophils, eosinophils, monocytes/macrophages, dendritic cells, mast cells, and lymphocytes (13). To produce LTs, 5-LO acts on arachidonic acid, converting it to leukotriene A 4 (LTA 4 ). LTA 4 is then converted into leukotriene B 4 (LTB 4 ) or leukotriene C 4 (LTC 4 ), molecules that are exported from the cell (14). LTs are produced at the initial steps of the acute inflammatory response and act predominantly as proinflammatory lipid mediators. LTB 4 , for example, attracts neutrophils, monocytes, and lymphocytes to the site of inflammation and induces edema formation by increasing vascular permeability and plasma leakage at the site of inflammation (15-18). In contrast to LTs, production of LXs is dependent on cell-cell interaction by a process known as transcellular biosynthesis and requires the interaction between 5-LO and 15-or 12-lipoxygenase (15-LO or 12-LO, respectively) (19). Production of LXs by 5-15-LOs begins in eosinophils, monocytes, or epithelial cells (18). The 15-LO metabolic product, 15S-hydroperoxyeicosatetraenoic acid (15S-HPETE), is released by these cells, taken up by polymorphonuclear cells or monocytes, and then processed by 5-LO into bioactive lipoxin A 4 (LXA 4 ) or lipoxin B 4 (LXB 4 ). Production of LXs by 15-12-LO occurs after arachidonic acid conversion to LTA 4 by 5-LO in leukocytes. LTA 4 is taken up by platelets and transformed to LXA 4 and LXB 4 via 12-LO activity (20). LXs act as anti-inflammatory and proresolution lipid mediators, by inhibiting both neutrophil and eosinophil transmigration into sites of infection and by promoting the noninflammatory infiltration of monocytes that is required for resolution and wound healing (21-23). LXs also stimulate macrophages to ingest and clear apoptotic neutrop...